Merck’s Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark’s Luxturna overpriced, ICER says
Five things for pharma marketers to know: Thursday, December 21, 2017
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche’s breast cancer combo therapy
Five things for pharma marketers to know: Tuesday, December 19, 2017
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
Five things for pharma marketers to know: Monday, December 18, 2017
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter’s Vraylar sees positive results for bipolar depression
Five things for pharma marketers to know: Friday, December 15, 2017
FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly’s Humalog; drugmakers allegedly hired nurses to promote drugs
Five things for pharma marketers to know: Friday, December 8, 2017
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
Five things for pharma marketers to know: Wednesday, December 6, 2017
FDA approves Novo’s diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
Five things for pharma marketers to know: Tuesday, December 5, 2017